Advancement of subtype-based early breast cancer systematic therapy
Molecular subtype-guided therapy—combining targeted drugs and immunotherapy—transforms early breast cancer treatment options.
This review comprehensively covers advances in systemic therapy for early breast cancer organized by molecular subtype, highlighting how targeted agents, immunotherapy, and combinatorial strategies have transformed treatment options. The article synthesizes recent trial results and translates them into practical treatment considerations for early breast cancer management.
What the study was
- Study design
- Narrative review
- Population
- Early-stage breast cancer patients across HR+/HER2-, HER2+, and TNBC molecular subtypes
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Zhonghua yi xue za zhi
Why it surfaced
Comprehensive subtype-based early breast cancer systemic therapy review; useful for pipeline context on standard-of-care landscape in a high-volume disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.